Specific ethnic genetic backgrounds are associated with the risk of Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN) especially in Asians. However, there have been no large cohort, multiple-country epidemiological studies of medication risk related to SJS/TEN in Asian populations. Thus, we analyzed the registration databases from multiple Asian countries who were treated during 1998-2017. A total 1,028 SJS/TEN cases were identified with the algorithm of drug causality for epidermal necrolysis. Furthermore, those medications labeled by the US Food and Drug Administration (FDA) as carrying a risk of SJS/TEN were also compared with the common causes of SJS/TEN in Asian countries. Oxcarbazepine, sulfasalazine, COX-II inhibitors, and strontium ranelate were identified as new potential causes. In addition to sulfa drugs and beta-lactam antibiotics, quinolones were also a common cause. Only one acetaminophen-induced SJS was identified, while several medications (e.g., oseltamivir, terbinafine, isotretinoin, and sorafenib) labeled as carrying a risk of SJS/ TEN by the FDA were not found to have caused any of the cases in the Asian countries investigated in this study.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions and are mainly related to medications. Thus far, several drugs have been reported to carry a risk of causing SJS/TEN and have been labeled by the US Food and Drug Administration (FDA) according to their differing levels of risk, including potential adverse reactions, precautions, and boxed warnings. For the purposes of such labeling, it is of course imperative that those drugs that carry any risk of inducing SJS/TEN be clearly identified.
Recent studies have shown that different ethnic populations may have different risks of medication-induced SJS/TEN. For example, strong associations between medications and specific HLA alleles have been identified in Asian populations. [1] [2] [3] [4] HLA-B*15:02 and HLA-B*58:01 are common HLA alleles among Asian populations and have been found to be strongly associated with carbamazepineand allopurinol-induced SJS/TEN, respectively, in Asian populations. 5, 6 The frequencies of these specific alleles have also been found to be correlated with the increased risks of SJS/TEN induced by carbamazepine and allopurinol in Asian populations. 7, 8 However, the strong HLA-B*15:02 association with carbamazepineinduced SJS/TEN was not found in European populations. 9 Instead, HLA-A*31:01 was found to be a specific predictor for carbamazepine-hypersensitivity reaction in Europeans. 10 Relatedly, the European case-control surveillance of SCAR (EuroSCAR) group published a study reporting the high-risk medications found to be involved in 379 validated cases of SJS/TEN between 1997 and 2001 in six countries (Austria, France, Germany, Israel, Italy, and the Netherlands). 11 The same study also introduced the algorithm of drug causality for epidermal necrolysis (ALDEN) for the assessment of drug causality in SJS/TEN. 11 Nonetheless, multiple-country, large cohort studies of medication risks related to SJS/TEN in Asian countries have not yet been available, even as the numbers of Asian immigrants to locations worldwide have increased substantially in recent years due to globalization. In light of the correspondingly greater numbers of Asian SJS/TEN patients that will be seen in the US, Europe, and elsewhere in the world, a large epidemiological study of SJS/TEN causality in Asian populations is indispensable. In this study, therefore, an SJS/TEN research consortium including participants from a number of Asian countries, namely, Taiwan, Thailand, Japan, Malaysia, Singapore, Hong Kong, the Philippines, and mainland China, aimed to establish risk profiles for medications related to SJS/TEN in Asians and, furthermore, to compare those risk profiles with those for European populations and those for drugs labeled as carrying risks for SJS/TEN by the FDA.
RESULTS

Causative drugs for SJS/TEN in registration databases
Among the investigated SJS/TEN registration databases from Taiwan, Thailand, Japan, Malaysia, Singapore, Hong Kong, the Philippines, and mainland China (Fujian), there were a total of 1,028 validated cases of SJS/TEN with probable or definite drug causality as defined by ALDEN scores. Moreover, a total of 61 drugs were identified as being probably or definitely related to those validated cases of SJS/TEN. We categorized these drugs into four groups: 1) antiepileptic drugs/antipsychotics, 2) antibiotics/antiviral agents, 3) nonsteroidal antiinflammatory drugs (NSAIDs), and 4) allopurinol and others ( Table 1) . The percentage of cases associated with each category of drugs is shown in Figure 1a . Antiepileptic drugs/antipsychotics (53%) were found to be the category of drugs that most commonly caused the SJS/TEN cases in Asians reviewed in this study, while antibiotics/antiviral agents (20%) and allopurinol (19%) were the drugs that caused the second and third highest percentages of cases, respectively.
Antiepileptic drugs/antipsychotics related to SJS/TEN in Asian countries
The antiepileptic drugs/antipsychotics were responsible for the largest proportion of SJS/TEN cases ( Table 1) , with carbamazepine being the drug in this category most relevant to SJS/TEN. Oxcarbazepine was found to pose a new threat of SJS/TEN in Asians, especially in Taiwan. It should be noted that the FDA relabeled the drug information for carbamazepine in 2007 after the identification of the strong association between HLA-B*15:02 and carbamazepine-induced SJS/TEN in Han Chinese, advising that patients with Asian ancestry be screened for HLA-B*15:02 before being treated with carbamazepine. 12 Meanwhile, some commonly prescribed antiepileptic drugs/antipsychotics that were labeled by the FDA as potentially causing SJS/TEN were not identified as being relevant to any of the cases in the investigated databases from the Asian countries (e.g., clobazam, duloxetine hydrochloride, and sertraline).
Antibiotics/antiviral drugs related to SJS/TEN in Asian countries
Antibiotics/antiviral drugs were found to cause a fairly high proportion of the cases investigated in this study ( Table 1) . Of the drugs in this category, sulfamethoxazole was responsible for the highest proportion of cases, and was noted to have caused some proportion of the cases in the databases from each of the countries. Consistent with a previous report, 13 the findings of the current study indicated that beta-lactam antibiotics (cephalosporins and aminopenicillins) and quinolones also caused relatively high proportions of the SJS/TEN cases in Asians investigated in this study, indicating that clinicians should pay careful attention to this potential complication when treating patients with these drugs. Clarithromycin was found to pose a new threat of SJS/ TEN in the investigated Asian populations. Meanwhile, rifampicin (four cases) and streptomycin (one case) were identified as causative drugs in spite of not being labeled as potential causes of SJS/TEN by the FDA. In contrast, terbinafine, oseltamivir, and some other commonly used antibiotics that were labeled by the FDA as potentially causing SJS/TEN were not identified as being relevant to any of the identified cases in our registration databases. These drugs are listed in Table 1 .
NSAIDs related to SJS/TEN in Asian countries
NSAIDs are more widely used but were found to be less frequently causative of SJS/TEN. Ten drugs belonging to this class of drugs were found to be related to at least some of the SJS/TEN cases in our registration databases ( Table 1) . COX-II inhibitors, including etoricoxib (seven cases; not approved by the FDA) and celecoxib (four cases), were among the culprits causing SJS/TEN. On the other hand, there were also other NSAIDs that were labeled by the FDA as potentially causing SJS/TEN that were not identified as being relevant to any of the identified cases in the databases of the investigated Asian countries, including valdecoxib, diflunisal, fenoprofen calcium, indomethacin, ketoprofen, ketorolac, oxaprozin, sulindac, and tolmetin sodium.
Allopurinol-induced SJS/TEN in Asian countries
Allopurinol was the single drug found to cause the second highest proportion of SJS/TEN cases (after carbamazepine) in the Asian countries, accounting for 19.65% of the SJS/TEN cases ( Figure 1a and Table 1 ). Allopurinol is commonly used for the treatment of Other FDA labeled antibiotics/antiviral agents not identified in the Asian countries' databases: Telaprevir, gemifloxacin mesylate, griseofulvin ultramicrosize, ofloxacin, quinine sulfate, terbinafine, fosamprenavir calcium, darunavir ethanolate, delavirdine mesylate, efavirenz, etravirine, maraviroc, oseltamivir phosphate, peginterferon alfa-2a, raltegravir potassium, ritonavir, abacavir-lumivudine, and minocycline hydrochloride. f Other FDA labeled NSAIDs not identified in the Asian countries' databases: valdecoxib, diflunisal, fenoprofen calcium, indomethacin, ketoprofen, ketorolac, oxaprozin, sulindac, and tolmetin sodium. g Other labeled drugs not identified in the Asian countries' databases: acetazolamide, aldesleukin, alogliptin benzoate, amifostine, cysteamine bitartrate, dorzolamide hydrochloride, fenofibrate, glimepiride, isotretinoin, leflunomide, lenalidomide, propranolol hydrochloride, silver sulfadiazine, teriflunomide, thiabendazole, tramadol hydrochloride, sorafenib tosylate, bendamustine hydrochloride, chlorambucil, ibritumomab tiuxetan, pralatrexate, regorafenib, rituximab, vandetanib, vemurafenib, ipilimumab, and sitagliptin. NSAIDs, nonsteroidal antiinflammatory drugs; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
hyperuricemia and gouty arthritis worldwide. On the other hand, no other antihyperuricemic agents were identified as causative drugs responsible for any of the SJS/TEN cases investigated in this study.
Other medications related to SJS/TEN in Asian countries
Other medications found to carry a risk of inducing SJS/TEN are listed in Table 1 , including allopurinol (202 cases), sulfasalazine (19 cases), proton pump inhibitors (PPI) (10 cases), strontium ranelate (eight cases), erlotinib hydrochloride (one case), dimercaptopropane (one case), carbocysteine (one case), acetylcysteine (one case), acetaminophen (one case), and hydroxychloroquine (one case). Esomeprazole (eight cases) was the single drug found to be most commonly involved in PPI-induced SJS/TEN. Strontium ranelate, which is not approved by the FDA, was found to have resulted in eight of the cases of SJS/TEN investigated in this study.
Comparison of major drug causality of SJS/TEN between Asian countries and European countries
Differences between Asian countries and European countries were found in the drug causality of SJS/TEN. For example, carbamazepine accounted for 26.07% of the SJS/TEN cases in Asian countries investigated in this study, while only accounting for 11.39% of such cases in European countries. Lamotrigine was the fourth most common culprit of SJS/TEN in the cases from Asian countries investigated in this study but has not previously been identified as a major culprit in European countries. In contrast, phenobarbital and nevirapine pose higher risks of causing SJS/TEN in European countries than they were found to pose in the Asian countries included in this study. A comparison of drugs most commonly found to cause SJS/TEN in Asian countries with those most commonly found to cause SJS/ TEN in European countries is shown in Figure 1b . The proportions of SJS/TEN cases caused by different drugs in the individual Asian countries investigated in this study are shown in Figure 2 .
Comparison with FDA labeling
In total, 49 of the 61 (80.3%) drugs found to have caused at least one of the SJS/TEN cases investigated in this study have been labeled by the FDA as potentially causing SJS/TEN (with the drugs labeled as such having been identified via the Drugs@FDA and FDA Label Search functions of the FDA website). Meanwhile, four of the drugs identified as causative agents in this study have not been labeled as potential causative agents by the FDA, including tetracycline, rifampicin, streptomycin, and acetylcysteine. Furthermore, seven drugs identified as causative agents in this study, namely, floxacillin, cefamezine, etoricoxib, metamizole, strontium ranelate, carbocysteine, and dimercaptopropane, have not been approved for use by the FDA. A boxed warning, the strongest warning provided by the FDA, is used to highlight any potential adverse reactions to a given drug that are particularly serious in proportion to the potential benefit of using the drug, as well as those potential adverse reactions that can be prevented/reduced in frequency/severity through appropriate use of the drug. Such a warning indicates that the FDA has approved the drug for use, but only with certain restrictions in order to ensure safe use. Among the cases of SJS/TEN investigated in our study, six drugs were labeled with a box warning by the FDA: carbamazepine, lamotrigine, sulfadoxine/pyrimethamine, nevirapine, valdecoxib, and telaprevir. However, none of the SJS/TEN cases identified in this study were found to be related to valdecoxib and telaprevir use. 028 cases of SJS/TEN were identified in the Asian countries included in this study. In 1,006 cases, a single drug was implicated as having probable or definite causality. The other 22 cases had two drugs that were implicated as having probable or definite causality. These drugs were classified into five groups: 1) antiepileptic drugs and antipsychotics, 2) antibiotics/ antiviral agents, 3) nonsteroidal antiinflammatory drugs (NSAIDs), 4) allopurinol, and 5) others. Antiepileptic drugs/antipsychotics (53%) were found to be the most common category of drugs that caused the SJS/TEN cases in Asians in this study. (b) We compared the Asian cohort in this study with the Euro-SCAR European cohort of 237 published SJS/TEN cases 11 in terms of drug causality. We selected those drugs implicated as causative in more than 5% of cases for further comparison. Carbamazepine, allopurinol, and phenytoin were found to be the highly prevalent drugs to cause SJS/TEN in both Europeans and Asians. Phenobarbital caused more cases of SJS/TEN in European countries, while lamotrigine was more dominant to cause SJS/TEN in Asian countries in this study. SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
DISCUSSION
In the Asian populations investigated in this study, carbamazepine, allopurinol, phenytoin, lamotrigine, and sulfamethoxazole were the drugs most frequently found to be related to SJS/TEN (>50% of cases). Moreover, differences were found to exist between the drugs causing SJS/TEN in the investigated Asian countries and those causing European cases of SJS/TEN. Some differences were also found to exist between the drugs found to cause SJS/TEN in Asians and those labeled by the FDA as potential causes of SJS/TEN. We consider prescription preferences, approval differences, genetic variation, and regional environmental backgrounds to be the main factors behind these differences.
Carbamazepine and oxcarbazepine were significantly associated with SJS/TEN in the investigated Asian countries. This was consistent with a previous postmarket safety study conducted by the FDA in 2007 that reported a relatively high risk (more than 10 times) of carbamazepine to induce SJS or TEN in Asian populations compared with Caucasians.
14 This could be attributed to the strong genetic association between carbamazepineinduced SJS/TEN and the HLA-B75 serologic type, allele HLA-B*15:02, which is a highly prevalent in Asian populations except Japanese. 15 After the genetic marker HLA-B*15:02 was found to be associated with carbamazepine-induced SJS/TEN in Han Chinese in 2004, several Asian countries have improved drug safety policy of the health system for carbamazepine. However, only some Asian areas are capable of genetic tests (HLA-B*15:02) with a comprehensive and national implementation (e.g., Taiwan and Hong Kong) and most of the policies have only been advocated in recent years. In Taiwan, HLA-B*15:02 screening has been turned into a guideline-based test and the cost of the genetic test has been covered by the Bureau of National Health Insurance in Taiwan since 2010. The indication of carbamazepine was modified to be limited to epilepsy, trigeminal neuralgia, nephrogenic Figure 2 Proportions of SJS/TEN cases caused by different common drugs in individual Asian areas. This figure shows the proportions of SJS/TEN cases caused by the common causative drugs in each Asian country. The major causes of SJS/TEN identified in this study included carbamazepine, allopurinol, phenytoin, lamotrigine, sulfamethoxazole, aminopenicillins, phenobarbital, and cephalosporins. Carbamazepine, allopurinol, or phenytoin were the most common causative drugs among all Asian countries in this study. In contrast, lamotrigine was the most common causative drug for SJS/TEN in Japan. SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis. diabetic insipidus, and bipolar disorder. The identification of subjects carrying the HLA-B*15:02 allele and further avoidance of carbamazepine therapy in these subjects was strongly associated with a decrease in the incidence of carbamazepine-induced SJS/ TEN. 16 Supplemental Figure S1 shows the evolutional changes of carbamazepine-induced SJS/TEN in Taiwan in this study period. In Hong Kong, the genetic test with HLA-B*15:02 policy was implemented for newly commenced carbamazepine or other antiepileptic drugs since 2008. 17 The screening policy was also associated with prevention of carbamazepine-induced SJS/TEN. For Singapore, the Ministry of Health (MOH) and HSA highly recommend genotyping for the HLA-B*15:02 allele prior to initiation of carbamazepine in Singapore. 18 In Thailand, several specialists also recommended physicians screen for the HLA-B*15:02 allele before giving carbamazepine. 19, 20 These health system policies or recommendation changes could reduce the cases of carbamazepine-induced SJS/TEN, and had been proved in Taiwan and Hong Kong. 17,21 Furthermore, we also found that these health system policies or recommendations changes might also affect the prescription preference. Table S1 shows the drug consumption of antiepileptics in Taiwan from the National Health Insurance database in the past 12 years. A significant decline of carbamazepine use and increased valproic acid and oxcarbazepine was found after 2010, when the genetic test for HLA-B*15:02 has been covered by the national health insurance in Taiwan.
Oxcarbazepine, a structural analog of carbamazepine, is considered to be better tolerated than carbamazepine due to different metabolic pathways. 22, 23 In this study, the cases of oxcarbazepineinduced SJS/TEN was much lower than that of carbamazepineinduced SJS/TEN, but oxcarbazepine-induced SJS/TEN was rarely seen. Being a relatively new antiepileptic drug, it is likely that oxcarbazepine simply constitutes a new threat in Asian populations, especially in Taiwan and Thailand. 24 The association of oxcarbazepine-induced SJS/TEN and HLA-B*15:02 has also been found to be genotype-phenotype-specific. 24 Lamotrigine was also a major cause of SJS/TEN in the investigated Asian countries. Interestingly, we found that lamotrigineinduced SJS/TEN occurred in Japan at a significantly higher rate than in the other Asian countries in this study, as well as in European populations. A previous case-control study from Japan revealed that the frequencies of genotypes HLA-DRB1*04:05, -DQB1*04:01 and -DQA1*03:03 were higher in the patients with lamotrigine-induced cutaneous adverse drug reactions than in other Japanese populations. 25 As such, whether this genetic association between lamotrigine-induced SJS/TEN and the aforementioned genotypes contributed to the high rate of lamotrigine-induced SJS/TEN in the Japanese population in this study requires further investigation.
Trimethoprim and sulfamethoxazole are usually dosed as a single tablet as cotrimoxazole. Among the two regimens, sulfamethoxazole is one of the most common culprit drugs for SJS/TEN in several countries. 26 Recently, three HLA alleles: HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01, were found to be significantly more common in the sulfamethoxazole-induced SJS/TEN patients compared with controls in the Thai population. 26 Whether these HLA alleles are associated with sulfamethoxazoleinduced SJS/TEN in other Asian populations needs to be further investigated. Trimethoprim, the other regimen of cotrimoxazole, was regarded as less likely to induce SJS/TEN. 27 In that study, sulfamethoxazole was identified as the culprit drug of all the SJS/ TEN cases after taking cotrimoxazole based on the ALDEN scoring system. However, a study recently observed a strong association between SJS/TEN and trimethoprim alone. 28 A further investigation whether trimethoprim alone would induce SJS/ TEN in Asian countries is needed. In addition, other antibiotics that are widely used in Asian countries, including quinolones, aminopenicillins, and cephalosporins, also accounted for a considerable number of SJS/TEN cases.
Several studies have reported that nevirapine, one of the firstgeneration nonnucleoside reverse transcriptase inhibitors (NNRTIs) widely used to fight AIDS by blocking the replication of HIV, has the potential to cause SJS/TEN. 29 The FDA has also included this severe adverse effect in its boxed warning for the drug since 2000. 30 In our study, however, a much lower frequency of nevirapine-induced SJS/TEN was found in the Asian countries included in the study than has previously been found in European countries. Relatedly, previous investigations have revealed an association between some immunogenetic (HLAallelotypes) factors and SJS/TEN. Specifically, the HLA-C*04:01 allele was found to be associated with the hypersensitivity reaction in differing ethnicities; the HLA-B*35 allele was found to be associated with the hypersensitivity reaction in the Thai population; and the HLA-DRB1*01 allele was found to be associated with the hypersensitivity reaction in white populations. [31] [32] [33] Under the current guidelines 34 for HIV treatment, nevirapine is no longer the first-line medication in Asians. But nevirapine was also until recently a first-line agent for the treatment of HIV in Africa and is still used in specific populations such as pregnancy and extensively drug-resistant tuberculosis. The prevalence of nevirapine-induced SJS/TEN is higher in Africa, where the prevalence of HIV is 25% in some countries. In this study, only two cases of nevirapine-induced SJS/TEN were identified. The low nevirapine-induced SJS/TEN in Asian countries may be related to the frequency of nevirapine use in Asian countries. However, it has been reported that nevirapine can cause more cases of drug reaction with eosinophilia and systemic symptoms complex (DRESS) than SJS/TEN in Thailand. 35 Clinicians still have to be aware of nevirapine-induced DRESS in Asian populations.
Strontium ranelate, while not approved by the FDA, is registered as a prescription drug in more than 70 countries and provides an option for the treatment of postmenopausal osteoporosis. However, it has been reported to be associated with SJS/TEN in Asian countries, such as Singapore and Taiwan. 36, 37 Meanwhile, Cacoub et al. reported a series of cases of strontium ranelateinduced SCAR, including five cases of SJS/TEN and 47 cases of DRESS from European countries. 38 Relatedly, the results of this study reveal a potential emerging threat of strontium ranelateinduced SJS/TEN in Asian countries.
COX-II inhibitors are increasingly used to reduce the risk of peptic ulcer, and their risk of causing SJS/TEN in Western countries was summarized in a previous study. 39 In a review of US cases of SJS/TEN, 63 cases were reported to involve valdecoxib use, 43 were reported to involve celecoxib, and 17 were reported to involve rofecoxib. Valdecoxib and rofecoxib were subsequently withdrawn from the market due to this potential adverse event. In this study, we also identified an association between SJS/TEN and celecoxib. Furthermore, etoricoxib, which is not approved for use in the US, was also identified as a new potential cause of SJS/TEN in Asian countries.
As the most commonly used analgesic and antipyretic overthe-counter drug, the association between acetaminophen and SJS/TEN has been debated by specialists for a long time, with few cases having been reported. In this study, one case of acetaminophen-induced SJS/TEN overlap was identified in the investigated Asian SCAR registration databases by the ALDEN scoring system, and this case also involved recurrent SJS/TEN after rechallenging.
Some drugs are usually used together for combination therapies. We deem that the risks of SJS/TEN for these drugs are actually higher than our data indicated due to the difficulty of identifying the causative agent in such combined therapies when using ALDEN scoring. For instance, higher risks of SJS/TEN are possible for isoniazid, rifampin, and pyrazinamide, the drugs used in a triple combination therapy to treat tuberculosis. These drugs have all been reported to carry a risk of SJS/TEN and are widely used in Southeast Asia and the Western Pacific, which together account for a great proportion of the global incidence of tuberculosis (56% of new tuberculosis cases worldwide in 2013 40, 41 and 61% in 2015). The same state of affairs exists for new HIV drugs, which have evolved to highly active antiretroviral therapies (HAARTs) from monotherapies. In addition, PPIs are also commonly used in combination therapies for Helicobacter pylori eradication with clarithromycin or metronidazole and amoxicillin. In this study, esomeprazole was identified as the PPI most commonly involved in PPI-induced SJS/TEN in the investigated Asian countries, a finding that was also similar to that of our recent report for Taiwan alone. 42 Using in vitro lymphocyte activation test assays can help to identify the offending drugs in such situations, as well as any crossreactivity to structurally similar PPIs. 42 There were several limitations in this study. First, this study was analyzed based on the proportional reporting ratio instead of reporting odds ratio. The reporting odds ratio has some advantages over the proportional reporting ratio to prevent bias, especially assessing associations with rare events. However, this study enrolled cases from multiple countries in Asian populations across 10 years from 1998 to 2017. The exact drug users of the whole Asian population could vary from country to country, and it is difficult to analyze the data together. In addition, the data of exact drug users from the whole Asian population is difficult to access. Without the exact individual drug-using frequency, we are not able to calculate the reporting odds ratio. Second, it would be of interest to see region-specific data among different countries as well as pre-and postgenetic screening policy implementation. However, the condition and policy in different counties are variable. It is difficult to analyze this factor together with all the Asian countries enrolled. Although for the variable policy, the overall trend of drug causality should not be much different. Third, there are some limitations of the ALDEN score, especially for orphan or new medication-induced SJS/TEN cases, which could have lower scores as part of drug notoriety and fail to meet the probable or definite cases. To the best of our knowledge, this is the first study with a large sample size to investigate the profile of medication-related SJS/TEN in Asians, and we believe that this study is informative and may increase awareness of risk medications, especially for Asian populations.
In summary, we provide qualitative profiles for the various medications that can potentially cause SJS/TEN in Asian populations, in addition to comparing those profiles with the corresponding profiles indicated by a European cohort study and FDA labeling. The study results indicate a number of significant potential threats that are worthy of further investigation. The provided profiles could help to improve patient safety and increase awareness of clinicians of current medication risk related to SJS/TEN.
METHODS
Study design and study populations
We collected data regarding drug-induced SJS/TEN patients from various Asian SCAR consortium registration databases, including those of multiple medical centers in Taiwan, Thailand, Japan, Malaysia, Singapore, the Philippines, Hong Kong, and mainland China (Fujian), for the period from January 1998 to April 2017. This study was approved by the Institutional Review Board (IRB) of the study site. The cases in our registration databases were validated by dermatologists with detailed records including general information, mucocutaneous manifestations, and diagnoses.
The case registries were from the referred cases to the tertiary medical hospitals in these countries. The registration cases were mainly managed by our SJS/TEN experts from different Asian countries. Although there were cases reported by a spontaneous reporting system, these cases were also further validated by our SJS/TEN experts from different Asian countries. The cases in our registration databases were validated with detailed records including general information, diagnosis, mucocutaneous manifestations, pathologic results, drug index day, the exposure drugs as well as comedications, the duration of the drug exposure, whether prechallenge or rechallenge, outcomes, and lab data.
To get consensus on diagnosis SJS/TEN and identification of drug causality, there are some consortiums related to SJS/TEN established in Asian countries. Taiwan SCAR was established since 2013. Some of our Taiwan SCAR members have joined the RegiSCAR group since 2009 and regularly attended RegiSCAR biannual meetings at least once per year to evaluate registered SCAR (SJS/TEN or DRESS) cases by using consensus RegiSCAR SJS/TEN criteria. The Japan SCAR consortium was established since 2008, and some of our Taiwan SCAR members have joined the Japan SCAR biannual meeting since 2010. In addition, SEA-SCAR (Southeast Asian SCAR) was established since 2014 to conduct case surveillance among Malaysia, Singapore, the Philippines, and Thailand. Moreover, we have regular meetings at least once per year to evaluate registered SCAR (SJS/TEN or DRESS) cases by using consensus RegiSCAR SJS/TEN criteria. Additionally, Asian SCAR consortium members have attended the International Congress on Cutaneous Adverse Drug Reactions and discussed interesting cases from different countries, some important issues and controversies related to SCAR, and further made consensus for SCAR cases validation, definition, and management. 43, 44 There were a total of 1,863 cases in the registration databank; 552 patients were excluded based on missing data for SJS/TEN diagnosis or ALDEN scoring. Among the remaining 1,311 patients, 283 patients were excluded due to failure to meet the single probable or definite drug causality as defined by ALDEN scores. Therefore, a total of 1,028 cases were enrolled in this study.
Disease definition
A consensus definition of SJS/TEN provided by the international Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) group was used: An acute onset and rapid progression of painful lesions of the skin and mucous membranes that develop to blisters and erosions with severe constitutional symptoms and extensive detachment of the epidermis. 45, 46 Severity was defined according to the body surface area (BSA) affected. SJS is characterized by skin detachment of less than 10% of the BSA, TEN is defined by skin detachment of over 30% of the BSA, and skin detachment of between 10-30% is categorized as SJS-TEN overlap.
Causality assessment
The Naranjo algorithm and ALDEN are two major algorithms that are used to determine the causality of suspected adverse drug reactions. 11, 47 We adopted ALDEN scoring to assess the drug causality in this study because of its special emphasis on evaluating SJS and TEN. Several parameters were taken into account in producing the corresponding scores for this algorithm: delay from initial drug component intake to onset of reaction, drug present in the body on the index day, prechallenge/rechallenge, dechallenge, and drug notoriety. Then five categories, definite, probable, possible, unlikely, and very unlikely, were classified in accordance with the final score. Only patients with a probable or definite cause (that is, an ALDEN score 4) were included in our study.
Comparison with a European cohort indicating common risk medications related to SJS/TEN
We further compared the Asian cohort in this study with the Euro-SCAR European cohort of 379 published SJS/TEN cases 11 in terms of drug causality.
Survey of FDA labels
In order to identify those medications labeled by the FDA as carrying a risk of SJS/TEN, a list of 88 SJS/TEN labeled drugs were adopted from Hur et al. 48 and further mining of labels was conducted via the Drugs@FDA database and the FDA Label Search database. These databases include most of the drug products approved by the FDA, with patient information, labels, approval letters, reviews, and other information being made available.
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